Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-03-2024 | Hepatitis B | Case report

Azathioprine/vedolizumab

Various toxicities

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Lin WC, et al. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflammatory Bowel Diseases 29: 1730-1740, No. 11, Jan 2023. Available from: URL: https://dx.doi.org/10.1093/ibd/izac269 Lin WC, et al. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflammatory Bowel Diseases 29: 1730-1740, No. 11, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​1093/​ibd/​izac269
Metadata
Title
Azathioprine/vedolizumab
Various toxicities
Publication date
01-03-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55103-9

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Multiple drugs

Case report

Diclofenac

Case report

Aspirin/Warfarin

Case report

Prednisolone

Case report

Multiple drugs